SCO-267

SCO-267 is a novel, orally bioavailable small molecule that acts as a full agonist of the free fatty acid receptor 1 (GPR40, also known as FFAR1), a G-protein-coupled receptor expressed in pancreatic beta cells and enteroendocrine cells. By fully activating GPR40 at an allosteric site distinct from partial agonists like fasiglifam, SCO-267 stimulates the secretion of both islet hormones (insulin, glucagon) and gut hormones (glucagon-like peptide 1 [GLP-1], glucose-dependent insulinotropic polypeptide [GIP], and peptide YY). This broad hormonal stimulation leads to improved glycemic control, decreased fasting hyperglycemia, enhanced glucose tolerance, and potential weight loss. Preclinical studies show superior efficacy compared to partial agonists and DPP4 inhibitors. Clinical trials have demonstrated safety and tolerability with once-daily oral dosing in healthy adults and patients with diabetes. The drug is being developed for type 2 diabetes mellitus, obesity, and nonalcoholic steatohepatitis (NASH)[1][3][5][6].